We are live on ! Find out more
DYN icon

Dyne Therapeutics
DYN

227 hedge funds and large institutions have $3.4B invested in Dyne Therapeutics in 2026 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 100 increasing their positions, 60 reducing their positions, and 45 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 100 | Existing positions reduced: 60

2% less capital invested

Capital invested by funds: $3.48B → $3.4B (-$78.1M)

7% less first-time investments, than exits

New positions opened: 42 | Existing positions closed: 45

2% less funds holding

Funds holding: 232 → 227 (-5)

10.74% less ownership

Funds ownership: 124.57% → 113.83% (-11%)

29% less funds holding in top 10

Funds holding in top 10: 7 → 5 (-2)

83% less call options, than puts

Call options by funds: $769K | Put options by funds: $4.47M

Holders
227
Holders Change
-5
Holders Change %
-2.16%
% of All Funds
2.79%
Holding in Top 10
5
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-28.57%
% of All Funds
0.06%
New
42
Increased
100
Reduced
60
Closed
45
Calls
$769K
Puts
$4.47M
Net Calls
-$3.7M
Net Calls Change
-$596K

Top Buyers

1
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$228M
2
VPC
Vestal Point Capital
New York
+$66.9M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$40.3M
4
OAG
Orbis Allan Gray
Bermuda
+$33.8M
5
Fiera Capital (Canada)
Fiera Capital (Canada)
Quebec, Canada
+$23.8M

Top Sellers

1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$71.9M
2
SL
Siren LLC
Connecticut
-$22M
3
CS
Candriam SCA
Luxembourg
-$20.7M
4
VC
Vivo Capital
California
-$18.2M
5
Citadel Advisors
Citadel Advisors
Florida
-$16.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
GCP
251
GSA Capital Partners
United Kingdom
– -$615K -31,422 Closed
OF
252
Optimize Financial
California
– -$593K -30,310 Closed
Walleye Capital
253
Walleye Capital
New York
– -$543K -27,762 Closed
WG
254
Winton Group
United Kingdom
– -$417K -21,296 Closed
FRM
255
Fox Run Management
Connecticut
– -$322K -16,450 Closed
A
256
AlphaQuest
New York
– -$312K -15,963 Closed
BC
257
BIT Capital
Germany
– -$293K -15,000 Closed
Thrivent Financial for Lutherans
258
Thrivent Financial for Lutherans
Minnesota
– -$281K -14,365 Closed
BC
259
Bridgefront Capital
Texas
– -$235K -12,018 Closed
Verition Fund Management
260
Verition Fund Management
Connecticut
– -$204K -10,453 Closed
SCM
261
Soleus Capital Management
Connecticut
– -$196K -10,000 Closed
AB
262
Amalgamated Bank
New York
– -$76K -3,889 Closed
SO
263
STRS Ohio
Ohio
– -$50.9K -2,600 Closed
Daiwa Securities Group
264
Daiwa Securities Group
Japan
– -$8K -424 Closed
Optiver Holding
265
Optiver Holding
Netherlands
– -$7.73K -395 Closed
FISPB
266
Fideuram - Intesa Sanpaolo Private Banking
– -$3.91K -200 Closed
FHA
267
Flagship Harbor Advisors
Massachusetts
– -$3.91K -200 Closed
MCI
268
MRP Capital Investments
Georgia
– -$1.47K -75 Closed
PFBT
269
Parkside Financial Bank & Trust
Missouri
– -$1.37K -70 Closed
BIA
270
Bell Investment Advisors
California
– -$509 -26 Closed
AAP
271
Arax Advisory Partners
Colorado
– -$352 -18 Closed
DF
272
Dunhill Financial
United Kingdom
– -$17 -1 Closed
7 8 9 10
11

DYN Hedge Fund Activity: Q1 2026 in Review

227 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q1 2026, worth a combined $3.4B — down 2.2% from $3.48B a quarter earlier.

Sellers outnumbered buyers: 45 funds closed out of DYN and 42 opened new positions — a net loss of 3 holders — while 60 trimmed existing stakes and 100 added.

The largest buyer was T. Rowe Price Investment Management, adding an estimated $228M. The largest seller was Adage Capital Partners, cutting an estimated $71.9M.

  • 227 institutional investors held Dyne Therapeutics (DYN) as of Q1 2026, down from 232 in Q4 2025.
  • Funds reported $3.4B of Dyne Therapeutics stock for Q1 2026, down 2.2% quarter-over-quarter.
  • 42 funds opened new Dyne Therapeutics positions in Q1 2026 and 45 closed out, a net change of -3 holders.
  • The largest Dyne Therapeutics buyer in Q1 2026 was T. Rowe Price Investment Management, an estimated $228M added.
  • The largest Dyne Therapeutics seller in Q1 2026 was Adage Capital Partners, an estimated $71.9M sold.

Based on aggregated 13F filings for Q1 2026.